FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2335360019> ?p ?o ?g. }

• W2335360019 endingPage "e0151832" @default.
• W2335360019 startingPage "e0151832" @default.
• W2335360019 abstract "Background Cytotoxic chemotherapy can be very effective for the treatment of cancer but toxicity on normal tissues often limits patient tolerance and often causes long-term adverse effects. The objective of this study was to assist in the preclinical development of using modified, non-living bacterially-derived minicells to deliver the potent chemotherapeutic doxorubicin via epidermal growth factor receptor (EGFR) targeting. Specifically, this study sought to evaluate the safety and efficacy of EGFR targeted, doxorubicin loaded minicells (designated EGFRminicellsDox) to deliver doxorubicin to spontaneous brain tumors in 17 companion dogs; a comparative oncology model of human brain cancers. Methodology/Principle Findings EGFRminicellsDox were administered weekly via intravenous injection to 17 dogs with late-stage brain cancers. Biodistribution was assessed using single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI). Anti-tumor response was determined using MRI, and blood samples were subject to toxicology (hematology, biochemistry) and inflammatory marker analysis. Targeted, doxorubicin-loaded minicells rapidly localized to the core of brain tumors. Complete resolution or marked tumor regression (>90% reduction in tumor volume) were observed in 23.53% of the cohort, with lasting anti-tumor responses characterized by remission in three dogs for more than two years. The median overall survival was 264 days (range 49 to 973). No adverse clinical, hematological or biochemical effects were observed with repeated administration of EGFRminicellsDox (30 to 98 doses administered in 10 of the 17 dogs). Conclusions/Significance Targeted minicells loaded with doxorubicin were safely administered to dogs with late stage brain cancer and clinical activity was observed. These findings demonstrate the strong potential for clinical applications of targeted, doxorubicin-loaded minicells for the effective treatment of patients with brain cancer. On this basis, we have designed a Phase 1 clinical study of EGFR-targeted, doxorubicin-loaded minicells for effective treatment of human patients with recurrent glioblastoma." @default.
• W2335360019 created "2016-06-24" @default.
• W2335360019 creator A5001494841 @default.
• W2335360019 creator A5008758148 @default.
• W2335360019 creator A5021863838 @default.
• W2335360019 creator A5023193477 @default.
• W2335360019 creator A5024726678 @default.
• W2335360019 creator A5026033104 @default.
• W2335360019 creator A5052670897 @default.
• W2335360019 creator A5060537111 @default.
• W2335360019 creator A5067962267 @default.
• W2335360019 creator A5070867223 @default.
• W2335360019 creator A5071437258 @default.
• W2335360019 creator A5074385559 @default.
• W2335360019 creator A5074659015 @default.
• W2335360019 creator A5083131273 @default.
• W2335360019 creator A5085060826 @default.
• W2335360019 creator A5087036316 @default.
• W2335360019 creator A5089342949 @default.
• W2335360019 creator A5091099302 @default.
• W2335360019 creator A5091652642 @default.
• W2335360019 creator A5091757385 @default.
• W2335360019 date "2016-04-06" @default.
• W2335360019 modified "2023-10-18" @default.
• W2335360019 title "Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model" @default.
• W2335360019 cites W1509144440 @default.
• W2335360019 cites W1543790510 @default.
• W2335360019 cites W1582809885 @default.
• W2335360019 cites W1967034772 @default.
• W2335360019 cites W1971681203 @default.
• W2335360019 cites W1973213662 @default.
• W2335360019 cites W1973544766 @default.
• W2335360019 cites W1977253304 @default.
• W2335360019 cites W1983718760 @default.
• W2335360019 cites W1985466356 @default.
• W2335360019 cites W1985858988 @default.
• W2335360019 cites W1989544027 @default.
• W2335360019 cites W2002516695 @default.
• W2335360019 cites W2002889167 @default.
• W2335360019 cites W2014066737 @default.
• W2335360019 cites W2018779108 @default.
• W2335360019 cites W2019607817 @default.
• W2335360019 cites W2019637349 @default.
• W2335360019 cites W2025759815 @default.
• W2335360019 cites W2028119906 @default.
• W2335360019 cites W2029038516 @default.
• W2335360019 cites W2031240230 @default.
• W2335360019 cites W2036254354 @default.
• W2335360019 cites W2037571189 @default.
• W2335360019 cites W2039560640 @default.
• W2335360019 cites W2046874009 @default.
• W2335360019 cites W2052057182 @default.
• W2335360019 cites W2064349256 @default.
• W2335360019 cites W2066336297 @default.
• W2335360019 cites W2066640676 @default.
• W2335360019 cites W2069305891 @default.
• W2335360019 cites W2085692731 @default.
• W2335360019 cites W2093578147 @default.
• W2335360019 cites W2096287682 @default.
• W2335360019 cites W2100158834 @default.
• W2335360019 cites W2103289907 @default.
• W2335360019 cites W2117553516 @default.
• W2335360019 cites W2118044926 @default.
• W2335360019 cites W2127787180 @default.
• W2335360019 cites W2131536155 @default.
• W2335360019 cites W2139008103 @default.
• W2335360019 cites W2139713707 @default.
• W2335360019 cites W2141713308 @default.
• W2335360019 cites W2143739956 @default.
• W2335360019 cites W2143897427 @default.
• W2335360019 cites W2148276738 @default.
• W2335360019 cites W2152042738 @default.
• W2335360019 cites W2152172559 @default.
• W2335360019 cites W2160952303 @default.
• W2335360019 cites W2162439819 @default.
• W2335360019 cites W2560367415 @default.
• W2335360019 cites W293506793 @default.
• W2335360019 cites W4230643493 @default.
• W2335360019 cites W4230908322 @default.
• W2335360019 cites W4235987765 @default.
• W2335360019 cites W4362029913 @default.
• W2335360019 doi "https://doi.org/10.1371/journal.pone.0151832" @default.
• W2335360019 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4822833" @default.
• W2335360019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27050167" @default.
• W2335360019 hasPublicationYear "2016" @default.
• W2335360019 type Work @default.
• W2335360019 sameAs 2335360019 @default.
• W2335360019 citedByCount "57" @default.
• W2335360019 countsByYear W23353600192017 @default.
• W2335360019 countsByYear W23353600192018 @default.
• W2335360019 countsByYear W23353600192019 @default.
• W2335360019 countsByYear W23353600192020 @default.
• W2335360019 countsByYear W23353600192021 @default.
• W2335360019 countsByYear W23353600192022 @default.
• W2335360019 countsByYear W23353600192023 @default.
• W2335360019 crossrefType "journal-article" @default.
• W2335360019 hasAuthorship W2335360019A5001494841 @default.
• W2335360019 hasAuthorship W2335360019A5008758148 @default.

• next